Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
514 results about "Diabetic retinopathy" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A complication of diabetes where blood vessels in the eye are damaged.
Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors
InactiveUS20050043292A1Ease of preparation and detectabilityGood metabolic stabilityBiocideOrganic chemistryDiabetic retinopathyArthritis
The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (“DPP-IV”), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes, metabolic syndrome (syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Owner:PFIZER INC
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
InactiveUS6710040B1Easy to prepareEase of detectabilityBiocideOrganic chemistryAcute coronary syndromeDisease progression
The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Owner:PFIZER INC
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
InactiveUS6884890B2Improve anti-tumor effectGood treatment effectBiocideOrganic chemistryDiabetic retinopathyProtein kinase domain
Indazole compounds that modulate and / or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and / or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and / or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Owner:AGOURON PHARMA INC
Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides
InactiveUS20040110817A1Ease of preparation and detectabilityGood metabolic stabilityBiocideSenses disorderDiabetic retinopathyDisease progression
The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, hyperglycemia, impaired glucose tolerance, metabolic syndrome (Syndrome X or insulin resistance syndrome), glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.
Owner:PFIZER INC
(5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors
The present invention relates to compounds having the formula I: which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions. The compounds of the present invention are useful in treating angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
Owner:MERCK & CO INC
Tyrosine kinase inhibitors
The present invention relates to compounds which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
Owner:MERCK & CO INC
Tyrosine kinase inhibitors
The present invention relates to compounds which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
Owner:MERCK & CO INC
Method and apparatus for improving both lateral and axial resolution in ophthalmoscopy
Owner:UNIVERSITY OF ROCHESTER
Anti-human VEGF receptor Flt-1 monoclonal antibody
The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.
Owner:KYOWA HAKKO KIRIN CO LTD
Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
InactiveUS6919461B2Melt-holding vesselsGroup 4/14 element organic compoundsDiabetic retinopathyDisease
Indazole compounds that modulate and / or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and / or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and / or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Owner:AGOURON PHARMA INC
Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization
InactiveUS7517870B2High unmet needControl rateBiocideOrganic active ingredientsDiabetic retinopathyHedgehog signaling pathway
Owner:FOND AZIONE TELETHON
Dendrimers for sustained release of compounds
Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.
Owner:WAYNE STATE UNIV
Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
The present invention relates to compounds which inhibit, regulate and / or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, macular edema, retinal ischemia, inflammatory diseases, and the like in mammals.
![Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors](https://images-eureka.patsnap.com/patent_img/3d33d8fe-d3f5-4ead-a5b0-e3bb9a3e22d6/US07550470-20090623-C00001.png "Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors")
![Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors](https://images-eureka.patsnap.com/patent_img/3d33d8fe-d3f5-4ead-a5b0-e3bb9a3e22d6/US07550470-20090623-C00002.png "Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors")
![Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors](https://images-eureka.patsnap.com/patent_img/3d33d8fe-d3f5-4ead-a5b0-e3bb9a3e22d6/US07550470-20090623-C00003.png "Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors")
Owner:MERCK SHARP & DOHME CORP
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
InactiveUS20050106726A1Strong specificityIncrease serum stabilitySugar derivativesActivity regulationDiseaseDiabetic retinopathy
The present invention concerns methods and reagents useful in modulating platelet-derived endothelial cell growth factor (ECGF1) and / or platelet-derived endothelial cell growth factor receptor (e.g., ECGF1r) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against ECGF1 and / or ECGF1r gene expression and / or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, macular degeneration, diabetic retinopathy, and any other disease or condition that responds to modulation of ECGF1 and / or ECGF1r expression or activity.
Owner:SIRNA THERAPEUTICS INC
Text capture and presentation device
Embodiments of the invention provide devices and methods for capturing text found in a variety of sources and transforming it into a different user-accessible formats or medium. For example, the device can capture text from a magazine and provide it to the user as spoken words through headphones or speakers. Such devices are useful for individuals such as those having reading difficulties (such as dyslexia), blindness, and other visual impairments arising from diabetic retinopathy, cataracts, age-related macular degeneration (AMD), and glaucoma.
Owner:CARE INNOVATIONS LLC
System and method for automated funduscopic image analysis
ActiveUS20180315193A1Increase freedomProblem is complicatedImage enhancementImage analysisDiseaseVascular disease
A system and method of classifying images of pathology. An image is received, normalized, and segmented normalizing the image; into a plurality of regions; A disease vector is automatically determining for the plurality of regions with at least one classifier comprising a neural network. Each of the respective plurality of regions is automatically annotated, based on the determined disease vectors. The received image is automatically graded based on at least the annotations. The neural network is trained based on at least an expert annotation of respective regions of images, according to at least one objective classification criterion. The images may be eye images, vascular images, or funduscopic images. The disease may be a vascular disease, vasculopathy, or diabetic retinopathy, for example.
Owner:RETINOPATHY ANSWER LTD
Thiazolo-pyrimidine/pyridine urea derivatives
There are presented compounds of the formulaor a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.
Owner:F HOFFMANN LA ROCHE INC
Antidiabetic agents
A compound of the formula wherein R1 is: R5 is: and n, m, Z, R8, R9, R10 and R11 are as defined herein, useful in the treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly, myocardial ischemia.
Owner:GAMMILL RONALD B
Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
InactiveUS20080280987A1Inhibit angiogenesisSignificant cytotoxicityBiocideSenses disorderDiabetic retinopathyThiocolchicine
The invention provides methods of inhibiting angiogenesis in an individual by administering a composition (such as protein containing composition) comprising colchicine or thiocolchicine dimer. The composition is in an amount that is effective in inhibiting angiogenesis but is in some embodiments insufficient to induce significant cytotoxicity in the individual. The methods described herein are useful for treating angiogenesis-associated diseases, such as age-related macular degeneration, diabetic retinopathy, rheumatic arthritis, psoriasis, and cancer.
Owner:ABRAXIS BIOSCI LLC
Methods for treating acromegaly and giantism with growth hormone antagonists
The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants-have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype. The invention also describes methods of treating acromegaly, gigantism, cancer, diabetes, vascular eye diseases (diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, retinopathy of sickle-cell anemia, etc.) as well as nephropathy and other diseases, by administering an effective amount of a growth hormone antagonist. The invention also provides pharmaceutical formulations comprising one or more growth hormone antagonists.
Owner:OHIO UNIV EDISON ANIMAL BIOTECH INST
Amelioration of macular degeneration and other ophthalmic diseases
Methods for the treatment or prevention of a number of ocular diseases or disorders are disclosed. In particular, methods are disclosed for the amelioration of macular degeneration, diabetic retinopathy and other retinopathies, as well as uveitis, presbyopia, dry eye, glaucoma, blepharitis and rosacea of the eye. The methods comprise administration of a compositions comprising an ophthalmologically acceptable carrier or diluent and a hydoxylamine compound in a therapeutically sufficient amount to prevent, retard the development or reduce the symptoms of one or more of the ophthalmic conditions.
Owner:COLBY PHARMA CO
Treatment of leaky or damaged tight junctions and enhancing extracellular matrix
ActiveUS20080274979A1Promote growthPromote repairAntibacterial agentsSenses disorderDiseaseDiabetic retinopathy
Self assembling peptides and peptidomimetics can be utilized for the treatment and support of disorders associated with leaky or damaged tight junction and weak, diseased, or injured extracellular matrix. The self-assembling materials generally have alternating hydrophilic or hydrophobic residues or hydrophobic and / or hydrophilic sections which allow the material to react or interact with the glycoproteins found in the ECM. Diseases in which treatment with these materials applied to or near the site in need of treatment include diabetic retinopathy, sepsis, burns, and certain neurodegenerative diseases such as Parkinson's and Alzheimer's. The formulations can be administered by injection, spraying, topically or by catheter or via a wound dressing or other material to which it is applied and then applied to the site in need of treatment.
Owner:ARCH BIOSURGERY
Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds
InactiveUS20040002609A1Easy to cutMetabolism disorderPhosphorus organic compoundsDisease progressionDisease cause
The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV') inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.
Owner:PFIZER INC
Compositions and methods for treatment of diabetic retinopathy
InactiveUS20090155176A1Reducing and preventing macular edemaAvoid interactionPowder deliveryOrganic active ingredientsDiabetic retinopathyPsychiatry
The present invention provides compounds and methods for the treatment of diabetic retinopathy. In particular, LFA-1 antagonists are described herein to be used in the treatment of diabetic retinopathy. One aspect of the invention provides for diagnosis of diabetic retinopathy and administration of a LFA-1 antagonist, after the patient is diagnosed with diabetic retinopathy.
Owner:NOVARTIS AG
System for screening diabetic retinopathy
ActiveCN105513077AAutomated screening at scaleImprove diagnostic efficiencyImage enhancementImage analysisDiabetic retinopathySocial benefits
The invention provides a system for screening diabetic retinopathy. The system comprises an eyeground image obtaining device, an image processing and screening device and a report output device, wherein the eyeground image obtaining device is used for acquiring or receiving eyeground images of detected personnel; the image processing and screening device is used for processing the eyeground images and detecting whether pathology exists and then transmitting a detection result to the report output device; and the report output device outputs a corresponding detection report on the basis of the detection result. According to the system, the sensitivity of determining the diabetic retinopathy can reach 93.8%, the specificity can reach 94.5%, the precision is equivalent to manual determination precision, yet the detection time is greatly reduced, and the average detection time is 8.7 seconds, which is only one thirtieth of manual film reading time. Therefore, the scanning cost of the diabetic retinopathy can be substantially decreased, the diabetic retinopathy can be found early and treated early, the pain of patients is greatly reduced, and the clinical application prospect and the social benefits are quite good.
Owner:BEIJING DAHENG IMAGE VISION +1
Benzene compounds
InactiveUS20070105899A1Preventing, treating, and arresting the development of these diseasesExcellent ACC inhibiting activityBiocideSenses disorderDiabetic retinopathyDiabetic complication
The present invention provides novel benzene compounds presented by the following formulas, and analogs thereof, that exert an ACC activity-inhibiting effect that is effective in the treatment of obesity, hyperlipemia, fatty liver, hyperglycemia, impaired glucose tolerance, diabetes, diabetic complications (diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, and diabetic macroangiopathy, hypertension, arteriosclerosis), hypertension, and arteriosclerosis.
Owner:AJINOMOTO CO INC
Humanized antibodies against vascular endothelial growth factor
InactiveUS7667004B2High binding affinityInhibit cell proliferationPeptide librariesAntibody mimetics/scaffoldsDiabetic retinopathyAntigen
Methods are provided for designing and selecting antibodies against human antigens with high affinity and specificity in silico and in vitro. In some particular embodiments, methods are provided for designing and selecting humanized or fully human antibodies against vascular endothelial growth factor (VEGF) with high affinity and specificity. In another aspect of the invention, monoclonal antibodies against VEGF are provided. In particular, humanized or human anti-VEGF monoclonal antibodies are provided with ability to bind to human VEGF with high affinity, inhibit VEGF-induced proliferation of endothelial cells in vitro and inhibit VEGF-induced angiogenesis in vivo. These antibodies and their derivative can be used in a wide variety of applications such as diagnosis, prevention, and treatment of diseases such as cancer, AMD, diabetic retinopathy, and other diseases derived from pathological angiogenesis.
Owner:ABMAXIS
Micropulse grid pattern laser treatment and methods
ActiveUS20140228824A1Short durationLaser surgerySurgical instrument detailsDiabetic retinopathyMedicine
Owner:IRIDEX CORP
Dihydroxyl compounds and compositions for cholesterol management and related uses
Owner:ESPERION THERAPEUTICS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com